Mar 13, 2019 / 05:35PM GMT
Balaji V. Prasad - Barclays Bank PLC, Research Division - Director
Good afternoon. Continuing the session for the day. My name is Balaji from Barclays. And so we have with us today the management team from Amneal, including -- sorry, all right, there we go. So we have Rob Stewart, President and CEO; Paul Bisaro, Executive Chairman; and Todd Branning, SVP -- Senior Vice President and CFO. Gentlemen, thank you so much for taking the time out today. So the session will be in the form of a fireside chat, and our Q&As will be later on in the breakout session. And so before I launch into the sound of Q&As that we've discussed, Rob, would you like to kickstart off with some overview and comments.
Robert A. Stewart - Amneal Pharmaceuticals, Inc. - President, CEO & Director
Sure. First off, thank you for those attending here in person, as well as those that have dialed in via the webcast. I appreciate the time and the opportunity to meet with all of you. Summing up, 2018 was a transformational year for the company. We were starting with the Impax-Amneal deal
Amneal Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers